Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 1,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $25.04, for a total value of $25,040.00. Following the completion of the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $325,520. This trade represents a 7.14 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total transaction of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $28.56, for a total transaction of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $24,420.00.

Enliven Therapeutics Stock Performance

ELVN opened at $24.15 on Thursday. The firm has a market cap of $1.18 billion, a P/E ratio of -12.71 and a beta of 1.04. Enliven Therapeutics, Inc. has a fifty-two week low of $10.90 and a fifty-two week high of $30.03. The firm has a 50-day moving average of $24.74 and a 200 day moving average of $24.39.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Quest Partners LLC lifted its stake in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after purchasing an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after buying an additional 3,559 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Enliven Therapeutics during the 3rd quarter valued at $256,000. Verition Fund Management LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter worth $271,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Enliven Therapeutics in the 2nd quarter worth about $322,000. 95.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ELVN. Robert W. Baird increased their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, BTIG Research started coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.